DR. CHARLES EDWARD MCQUEEN, M.D.
Osteopathic Medicine in Washington, DC
License number
DC R6D70
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
2
6900 NW Borden Pavillion Walter Reed Army Medical Ctr, Washington, DC 20307
16805 Ethelwood Ter, Olney, MD 20832
16805 Ethelwood Ter, Olney, MD 20832
Phone
(202) 782-6389
(301) 774-1683
(301) 774-1683
Personal information
See more information about CHARLES EDWARD MCQUEEN at radaris.comName
Address
Phone
16805 Ethelwood Ter, Olney, MD 20832
Professional information
See more information about CHARLES EDWARD MCQUEEN at trustoria.com
Dr. Charles E Mcqueen, Washington DC - MD (Doctor of Medicine)
Dr. Charles E Mcqueen, Washington DC - MD (Doctor of Medicine)
Specialties:
Gastroenterology
Address:
6900 Georgia Ave NW, Washington 20307
(202) 782-6389 (Phone)
(202) 782-6389 (Phone)
Certifications:
Gastroenterology, 1983, Internal Medicine, 1981
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Washington Center / School of Medicine
Graduated: 1978
Mayo Clinic-Rochester
Walter Reed Army Med Ctr
Washington Center / School of Medicine
Graduated: 1978
Mayo Clinic-Rochester
Walter Reed Army Med Ctr
Charles Edward McQueen, Washington DC
Charles Edward McQueen, Washington DC
Specialties:
Gastroenterologist
Address:
6900 Georgia Ave Nw, Washington, DC 20307
Attn Medical Staff Credentials/Privileg, Bethesda, MD 20889
Attn Medical Staff Credentials/Privileg, Bethesda, MD 20889
Education:
Washington University, School of Medicine - Doctor of Medicine
Walter Reed Army Medical Center - Fellowship - Gastroenterology (Internal Medicine)
Walter Reed Army Medical Center - Fellowship - Gastroenterology (Internal Medicine)
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Gastroenterology (Internal Medicine)
Charles Edward McQueen, Washington DC
Charles Edward McQueen, Washington DC
Specialties:
Internal Medicine, Gastroenterology, Pulmonary Disease
Work:
Walter Reed Army Medical Center
6900 Georgia Ave Nw, Washington, DC 20307
6900 Georgia Ave Nw, Washington, DC 20307
Education:
Washington University at St. Louis (1978)
Chief Of Research At Jtf Capmed
Chief Of Research At Jtf Capmed
Position:
Chief of Research at JTF CAPMED, Chief of Research at JTF CapMed
Location:
Washington D.C. Metro Area
Industry:
Research
Work:
JTF CAPMED
-
Chief of Research
JTF CapMed
since 2008
-
Chief of Research
Walter Reed Army Institute of Research
2002 - 2006
-
Commander
Education:
Washington University in St. Louis School of Medicine 1974 - 1978
Doctor of Medicine (M.D.) University of Illinois at Urbana-Champaign 1970 - 1974
B.S., Biology, Chemistry & Physics
Doctor of Medicine (M.D.) University of Illinois at Urbana-Champaign 1970 - 1974
B.S., Biology, Chemistry & Physics
Therapeutic Treatment And Prevention Of Infections With A Bioactive Material(S) Encapuslated Within A Biodegradable-Bio-Compatable Polymeric Matrix
Therapeutic Treatment And Prevention Of Infections With A Bioactive Material(S) Encapuslated Within A Biodegradable-Bio-Compatable Polymeric Matrix
US Patent:
6902743, Jun 7, 2005
Filed:
Apr 6, 1998
Appl. No.:
09/055505
Inventors:
Jean A. Setterstrom - Alpharetta GA, US
Thomas R. Tice - Birmingham AL, US
Elliot Jacob - Silver Spring MD, US
Robert H. Reid - Kensington MD, US
John van Hamont - West Point NY, US
Edgar C. Boedecker - Crownsville MD, US
Phil Friden - Bedford MA, US
F. Donald Roberts - Dover MA, US
Charles E. McQueen - Olney MD, US
Apurba Bhattacharjee - Kensington MD, US
Alan Cross - Chevy Chase MD, US
Jerald Sadoff - Washington DC, US
Wendell Zollinger - Silver Spring MD, US
Thomas R. Tice - Birmingham AL, US
Elliot Jacob - Silver Spring MD, US
Robert H. Reid - Kensington MD, US
John van Hamont - West Point NY, US
Edgar C. Boedecker - Crownsville MD, US
Phil Friden - Bedford MA, US
F. Donald Roberts - Dover MA, US
Charles E. McQueen - Olney MD, US
Apurba Bhattacharjee - Kensington MD, US
Alan Cross - Chevy Chase MD, US
Jerald Sadoff - Washington DC, US
Wendell Zollinger - Silver Spring MD, US
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K009/14, A61K039/40, A61K009/48, A61K009/26, A61K009/16
US Classification:
424489, 424177, 424179, 424451, 424470, 424482, 424490
Abstract:
Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer having a molar composition of lactide/glycolide from 90/10 to 40/60, which may contain a pharmaceutically-acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging to ratios from 100/0 to 1/99.
Vaccines Against Diseases Caused By Enteropathogenic Organisms Using Antigens Encapsulated Within Biodegradable-Biocompatible Microspheres
Vaccines Against Diseases Caused By Enteropathogenic Organisms Using Antigens Encapsulated Within Biodegradable-Biocompatible Microspheres
US Patent:
2003016, Aug 28, 2003
Filed:
Aug 20, 2002
Appl. No.:
10/224125
Inventors:
Robert Reid - Kensington MD, US
Jean Setterstrom - Alpharetta GA, US
Edgar Boedeker - Crownsville MD, US
John VanHamont - Fort Meade MD, US
Charles McQueen - Olney MD, US
Frederick Cassels - Ellicott City MD, US
Jean Setterstrom - Alpharetta GA, US
Edgar Boedeker - Crownsville MD, US
John VanHamont - Fort Meade MD, US
Charles McQueen - Olney MD, US
Frederick Cassels - Ellicott City MD, US
International Classification:
A61K039/00, A61K009/50
US Classification:
424/491000, 424/184100
Abstract:
This invention relates to an immunostimulating composition comprising encapsulating microspheres, which may contain a pharmaceutically-acceptable adjuvant, wherein said microspheres having a diameter between 1 nanometer (nm) to 10 microns (um) are comprised of (a) a biodegradable-biocompatible poly(DL-lactide-co-glycolide) as the bulk matrix, wherein the relative ratio between the amount of lactide and glycolide components are within the range of 40:60 to 0:100 and wherein said poly (DL-lactide-co-glycolide) is present in an uncapped form and an end-capped form wherin a ratio of uncapped to end-capped forms is 99/1 to 1/99, and (b) an immunogenic substance comprising Colony Factor Antigen (CFA/II), hepatitis B surface antigen (HbsAg), or a physiologically similar antigen that serves to elicit the producton of antibodies in animal subjects. The preparation of its composition and its use as a vaccine is also disclosed.
Therapeutic Treatment And Prevention Of Infections With A Bioactive Materials Encapsulated Within A Biodegradable-Biocompatible Polymeric Matrix
Therapeutic Treatment And Prevention Of Infections With A Bioactive Materials Encapsulated Within A Biodegradable-Biocompatible Polymeric Matrix
US Patent:
6309669, Oct 30, 2001
Filed:
Jan 27, 1997
Appl. No.:
8/789734
Inventors:
Jean A. Setterstrom - Alpharetta GA
John E. Van Hamont - Fort Meade MD
Robert H. Reid - McComas CT
Elliot Jacob - Silver Spring MD
Ramasubbu Jeyanthi - Columbia MD
Edgar C. Boedeker - Chevy Chase MD
Charles E. McQueen - Olney MD
Daniel L. Jarboe - Silver Spring MD
Frederick Cassels - Ellicott City MD
William Brown - Denver CO
Curt Thies - Ballwin MO
Thomas R. Tice - Birmington AL
F. Donald Roberts - Dover MA
Phil Friden - Beford MA
John E. Van Hamont - Fort Meade MD
Robert H. Reid - McComas CT
Elliot Jacob - Silver Spring MD
Ramasubbu Jeyanthi - Columbia MD
Edgar C. Boedeker - Chevy Chase MD
Charles E. McQueen - Olney MD
Daniel L. Jarboe - Silver Spring MD
Frederick Cassels - Ellicott City MD
William Brown - Denver CO
Curt Thies - Ballwin MO
Thomas R. Tice - Birmington AL
F. Donald Roberts - Dover MA
Phil Friden - Beford MA
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 952, A61K 4730
US Classification:
424486
Abstract:
Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.
Extraction Process For Producing Plga Microspheres
Extraction Process For Producing Plga Microspheres
US Patent:
5705197, Jan 6, 1998
Filed:
Aug 16, 1996
Appl. No.:
8/698896
Inventors:
John Van Hamont - Ft. Meade MD
Curt Thies - Ballwin MO
Robert H. Reid - Kensington MD
Charles E. McQueen - Olney MD
Jean A. Setterstrom - Alpharetta GA
Curt Thies - Ballwin MO
Robert H. Reid - Kensington MD
Charles E. McQueen - Olney MD
Jean A. Setterstrom - Alpharetta GA
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 950
US Classification:
424501
Abstract:
A hybrid evaporation-extraction process for preparing microspheres of a p(DL-lactide-to-glycolide) biodegradable polymer, comprising:
a. preparing a lyophilized biologically active material-sucrose matrix; adding acetonitrile solvent to biologically active material-sucrose matrix to form a solution;
b. preparing a solution of a biodegradable poly (DL-lactide-co-glycolide) polymer by adding acetonitrile solvent to the polymer;
c. adding the biodegradable poly (DL-lactide-co-glycolide) polymer acetonitrile solution to the biologically active material-sucrose acetonitrile solution;
d. adding with stirring an oil containing lecithin to the poly (DL-lactide-co-glycolide) polymer-sucrose-biologically active material solution to evaporate acetonitrile and form an emulsion containing microspheres of poly (DL-lactide-co-glycolide) biodegradable polymers;
e. adding the emulsion from step d. into a solvent selected from heptane, hexane, pentane or isopropanol; and
f.
Therapeutic Treatment And Prevention Of Infections With A Bioactive Materials Encapsulated Within A Biodegradable-Biocompatible Polymeric Matrix
Therapeutic Treatment And Prevention Of Infections With A Bioactive Materials Encapsulated Within A Biodegradable-Biocompatible Polymeric Matrix
US Patent:
6844010, Jan 18, 2005
Filed:
Jul 18, 2000
Appl. No.:
09/618577
Inventors:
Jean A. Setterstrom - Alpharetta GA, US
John E. Van Hamont - Fort Meade MD, US
Robert H. Reid - Kensington MD, US
Elliot Jacob - Silver Spring MD, US
Ramasubbu Jeyanthi - Columbia MD, US
Edgar C. Boedeker - Chevy Chase MD, US
Charles E. McQueen - Olney MD, US
Daniel L. Jarboe - Silver Spring MD, US
Frederick Cassels - Ellicott City MD, US
William Brown - Denver CO, US
Curt Thies - Ballwin MO, US
Thomas R. Tice - Birmington AL, US
F. Donald Roberts - Dover MA, US
Phil Friden - Bedford MA, US
John E. Van Hamont - Fort Meade MD, US
Robert H. Reid - Kensington MD, US
Elliot Jacob - Silver Spring MD, US
Ramasubbu Jeyanthi - Columbia MD, US
Edgar C. Boedeker - Chevy Chase MD, US
Charles E. McQueen - Olney MD, US
Daniel L. Jarboe - Silver Spring MD, US
Frederick Cassels - Ellicott City MD, US
William Brown - Denver CO, US
Curt Thies - Ballwin MO, US
Thomas R. Tice - Birmington AL, US
F. Donald Roberts - Dover MA, US
Phil Friden - Bedford MA, US
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 950
US Classification:
424501, 424486, 424499, 424422, 424491, 424493, 424426, 514570, 514 2, 514 12, 530350, 530300
Abstract:
Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group, and end-capped forms ranging in ratios from 100/0 to 1/99.
“Burst-Free” Sustained Release Poly-(Lactide/Glycolide) Microspheres
“Burst-Free” Sustained Release Poly-(Lactide/Glycolide) Microspheres
US Patent:
7033608, Apr 25, 2006
Filed:
Jun 22, 1999
Appl. No.:
09/337945
Inventors:
John E. Van Hamont - Fort Meade MD, US
Phil Friden - Bedford MA, US
Robert H. Reid - Fairfield PA, US
F. Donald Roberts - Dover MA, US
Charles E. McQueen - Olney MD, US
Jean A. Setterstrom - Silver Spring MD, US
Phil Friden - Bedford MA, US
Robert H. Reid - Fairfield PA, US
F. Donald Roberts - Dover MA, US
Charles E. McQueen - Olney MD, US
Jean A. Setterstrom - Silver Spring MD, US
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 9/14, A61K 9/16, A61K 9/50
US Classification:
424490, 424489, 424491, 424493, 424496, 424501
Abstract:
Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1–100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer as a blend of uncapped (free carboxyl end group) and end-capped forms ranging in ratios from 100/0 to 1/99.